Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Deciphera Pharmaceuticals, Inc.    DCPH

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales - - 25,6 10,8 61,0
EBITDA -50,8 -104 -173 -177 -236
Operating profit (EBIT) -50,9 -104 -174 -217 -222
Pre-Tax Profit (EBT) -50,3 -99,9 -168 -207 -215
Net income -50,3 -99,9 -169 -214 -213
P/E ratio -7,58x -7,44x -8,34x -7,32x -8,32x
EPS ( $ ) -2,99 -2,82 -4,10 -4,68 -4,11
Dividend per Share (  ) - - - - -
Yield - - - - -
Reference price ( $ ) 22,670 20,990 34,230 34,230 34,230
Announcement Date 03/28/2018
08:01pm
03/14/2019
08:05pm
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - - - -
Finance 195 281 361 335 289
Operating income (EBITDA) -50,8 -104 -173 -177 -236
Leverage
(Debt/EBITDA)
- - - - -
Capital Expenditure 0,41 1,13 0,88 1,27 1,46
Free Cash Flow (FCF) -37,1 -87,9 -155 -188 -242
Book Value Per Share (BVPS) (  ) - 7,43 11,1 7,63 7,18
Cash Flow per Share (  ) - - -4,00 -4,75 -4,37
Announcement Date 03/28/2018
08:01pm
03/14/2019
08:05pm
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 1 734 M $ -
Entreprise Value (EV) 1 373 M $ 1 398 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) -8,34x -7,32x
Capitalization / Revenue 67,8x 160x
EV / Revenue 53,7x 127x
EV / EBITDA -7,95x -7,77x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,10x 4,48x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -680% -2 002%
Operating Leverage (Delta EBIT / Delta Sales) - -0,43x
Net Margin (Net Profit / Revenue) -660% -1 977%
ROA (Net Profit / Asset) -52,6% -66,7%
ROE (Net Profit / Equities) -60,7% -85,3%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   3,45% 11,7%
Cash Flow / Sales -793% -2 225%
Capital Intensity (Assets / Sales) 12,6x 29,6x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend